Boston Therapeutics is developing a pipeline of novel compounds to address unmet medical needs in diabetes. The company’s current product pipeline is focused on developing and commercializing the therapeutic molecules PAZ320 for patients with diabetes; and IPOXYNT for a wide rand of indications such as anemia and blood loss (injury), cardiovascular disease, and surgical blood supplementation.

Boston Therapeutics’ technology platform in applied carbohydrate chemistry has been pioneered by company CEO Dr. David Platt, who for the last 20 years has worked alongside scientific collaborators to safely address medical needs for oral and injectable applications.

Dr. Platt is recognized worldwide as an expert in carbohydrate chemistry and has led two drug candidates from concept to human clinical trials. He also founded three publicly traded companies: Pro-Pharmaceuticals, Inc., SafeScience, Inc., and International Gene Group. Dr. Platt’s guidance is supported by an executive management team with more than 100 years of combined experience.

Providing additional expertise, Boston Therapeutics has established a scientific advisory team with extensive expertise in complex carbohydrate chemistry, regulatory, and clinical development, with multiple submissions and approvals to U.S. Food and Drug Administration.

Under this leadership, Boston Therapeutics anticipates initiating a pivotal phase 3 study of PAZ320. The two-year study, to be conducted in the U.S., Europe, Hong Kong, Korea, and China, will be evaluate the effects of the drug candidate on glucose and hemoglobin A1c (HbA1c) in approximately 300 Type 2 patients currently taking metformin.

In an earlier phase 2 study, PAZ320 achieved a 40 percent reduction in post-meal blood glucose levels with no serious adverse events.

For additional information, visit www.BostonTI.com

Let us hear your thoughts below: